Track topics on Twitter Track topics that are important to you
The aim of this PMOS is to obtain further data on long-term safety, efficacy and the evaluation of quality of life outcomes of the HUMIRA-Pen in routine clinical use in patients with Moderate to Severe Chronic Plaque Psoriasis after unsustainable clinical response to other biological disease modifying anti-rheumatic drugs (BDMARDs). There are no data so far, showing the effects of switching from other BDMARDs to Humira in patients with Moderate to Severe Chronic Plaque Psoriasis. This study is to evaluate the long-term effectiveness of Humira in patients with moderate to severe chronic plaque psoriasis - by using the PASI - in patients who are pre-treated with efalizumab, infliximab or etanercept and who either never achieved satisfactory response, achieved satisfactory response initially, but lost it over time, discontinued treatment due to intolerance/side effect(s), or other reasons for example after regular stop of etanercept.
Observational Model: Cohort, Time Perspective: Prospective
Moderate to Severe Plaque Psoriasis
Site Reference ID/Investigator# 27435
Active, not recruiting
Published on BioPortfolio: 2014-08-27T03:15:18-0400
The main purpose of the current study will be to provide real - world evidence regarding the safety and effectiveness of secukinumab in the management of patients with moderate to severe c...
This is a multi-regional, randomized, double-blind, placebo-controlled, clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SHR-1314 in adults with ...
The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of tre...
Long term safety, efficacy and tolerability of ABT-874 in adults with moderate to severe psoriasis
To determine whether secukinumab can alter the activity of cytochrome P450 (CYP) 3A4 using midazolam as probe substrate in patients with moderate-to-severe plaque psoriasis.
Topical agents are the first-line therapy for psoriasis and treatment of choice for mild to moderate chronic plaque psoriasis. Patients with severe psoriasis often use topical therapies at least for s...
The recently updated dosing recommendation for adalimumab for moderate to severe plaque psoriasis states that patients with inadequate response to adalimumab every other week (EOW) after 16 weeks may ...
Short-term IL-23p19 inhibition by tildrakizumab improves plaque psoriasis and appears well-tolerated.
Topical corticosteroids are the mainstay of psoriasis treatment; long-term safety concerns limit use. Combination with tazarotene may optimize efficacy, minimizing safety/tolerability concerns, In pat...
The comparative effectiveness of available targeted immunomodulators for moderate-to-severe psoriasis has not been evaluated.
A humanized monoclonal antibody that binds to IL-12 and IL-23 and is used as a DERMATOLOGIC AGENT in the treatment of patients with plaque PSORIASIS who have not responded to other therapies.
A narcotic antagonist with analgesic properties. It is used for the control of moderate to severe pain.
Endovascular procedure in which atheromatous plaque is excised by a cutting or rotating catheter. It differs from balloon and laser angioplasty procedures which enlarge vessels by dilation but frequently do not remove much plaque. If the plaque is removed by surgical excision under general anesthesia rather than by an endovascular procedure through a catheter, it is called ENDARTERECTOMY.
An opioid analgesic used similarly to MORPHINE in the control of moderate to severe pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1097)
A group of tetraterpenes, with four terpene units joined head-to-tail. Biologically active members of this class are used clinically in the treatment of severe cystic ACNE; PSORIASIS; and other disorders of keratinization.
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...